Physician profile
Wade M Cooper
NPI 1124007208
$990,518.16
in general payments reported to CMS, 2019-2025
22 companies · $376K in 2025
The $376K reported for 2025 was more than what 99% of Neurology (Psychiatry & Neurology) providers received nationally (typical 2025 total: $454).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $49K · 2020: $27K · 2021: $41K · 2022: $52K · 2023: $168K · 2024: $277K · 2025: $376K.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Compensation For Services Other Than Consulting, Including Serving As Faculty Or As A Speaker At A Venue Other Than A Continuing Education Program: $375K · Honoraria: $275K · Consulting Fee: $112K · Travel and Lodging: $45K · Food and Beverage: $14K · Education: $175.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Compensation For Services Other Than Consulting, Including Serving As Faculty Or As A Speaker At A Venue Other Than A Continuing Education Program | $374,922.25 |
| Honoraria | $275,021.91 |
| Consulting Fee | $112,030.45 |
| Travel and Lodging | $45,293.12 |
| Food and Beverage | $13,644.47 |
| Education | $174.75 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Abbvie INC. | $308,787.51 | 2022-2025 | Qulipta, Ubrelvy, Botox |
| Lundbeck LLC | $256,494.32 | 2020-2025 | Vyepti |
| Lilly USA, LLC | $107,994.66 | 2019-2025 | Emgality, Reyvow, Amyvid |
| Pfizer INC. | $107,287.85 | 2023-2025 | |
| H. Lundbeck A S | $89,301.39 | 2021-2025 | Vyepti |
| Axsome Therapeutics, INC. | $56,451.72 | 2025 | Symbravo |
| Teva Pharmaceuticals USA, INC. | $20,878.46 | 2019-2025 | Ajovy |
| Eli Lilly and Company | $15,520.64 | 2019-2024 | |
| Biohaven Pharmaceutical Holding Company Ltd. | $7,164.97 | 2022 | |
| Amgen INC. | $5,598.64 | 2019-2024 | Aimovig |
| Biohaven Pharmaceuticals, INC. | $5,124.75 | 2021 | |
| Scilex Pharmaceuticals INC. | $4,338.44 | 2023-2024 | Ztlido |
| Biodelivery Sciences International, INC. | $3,000.00 | 2021 | |
| Tonix Medicines, INC. | $2,000.00 | 2023 | |
| Eisai INC. | $152.57 | 2023-2024 |
Show all 22 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Sumitomo Pharma America, INC. | $110.14 | 2023-2024 | Aptiom |
| Upsher-Smith Laboratories LLC | $95.22 | 2023 | |
| Otsuka America Pharmaceutical, INC. | $65.89 | 2023-2024 | Nuedexta |
| Allergan, INC. | $63.56 | 2019-2020 | |
| Sk Life Science, INC. | $45.26 | 2023 | |
| Vertex Pharmaceuticals Incorporated | $23.92 | 2025 | |
| Jazz Pharmaceuticals INC. | $18.25 | 2023 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Wade Cooper listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.